Checkpoint Inhibitor denied for failing step therapy by UnitedHealthcare?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What UnitedHealthcare typically requires
UnitedHealthcare's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The UnitedHealthcare angle on Checkpoint Inhibitor
## Why UnitedHealthcare Applies Step Therapy to Checkpoint Inhibitors — and Why You Can Appeal
Step-therapy (also called "fail-first") policies require that a patient try one or more alternative therapies before the plan will cover the requested agent. For checkpoint inhibitors, UnitedHealthcare may require prior treatment with other systemic agents — chemotherapy regimens, targeted therapies, or other immunotherapies — before approving a PD-1, PD-L1, or CTLA-4 inhibitor.
These denials are routinely overturned on appeal when the prescriber documents that: (a) the checkpoint inhibitor is a first-line standard of care per NCCN or other recognized oncology guidelines for the patient's specific tumor type, histology, and biomarker profile; or (b) the required prior therapy is medically contraindicated, clinically inappropriate, or was already tried and failed.
Many states have enacted step-therapy override laws requiring plans to grant exceptions when clinical evidence supports a different sequence. Even in states without such laws, the ERISA external review pathway allows an independent reviewer to assess whether the step requirement is consistent with generally accepted clinical standards.
## Federal Appeal Rights
- Internal appeal (ERISA §503 / ACA): File within 180 days of denial. Plan must respond within 60 days (30 days for pre-service).
- External review (ACA §2719): Available after the internal appeal is exhausted or upheld. Request within approximately 4 months of the final internal denial. Independent reviewers assess against clinical standards, not just plan policy.
- Expedited review: Request within 72 hours if clinically urgent.
## What to Gather
1. Guideline support for first-line use: Oncologist letter citing the applicable NCCN guideline category supporting this agent as a first-line or preferred option for the patient's diagnosis, histology, and biomarker status. 2. Biomarker and pathology documentation: Results establishing the molecular profile that drives regimen selection (e.g., PD-L1, TMB, MSI/MMR status). 3. Medical inappropriateness of required step(s): If the plan-required prior therapy is not appropriate, the prescriber should document the clinical rationale — contraindications, organ function, performance status, or histologic subtype for which the alternative is not guideline-supported. 4. Prior treatment history: If the required step was already attempted, provide dates, doses, duration, and outcome (progression, toxicity, intolerance). 5. UHC's published step-therapy policy: Identify every required prior step and the exception criteria. Map your documentation to each.
## Criteria-Mapping Structure
| UHC Step-Therapy Requirement | Your Documentation | |---|---| | Required prior agent(s) tried and failed | Treatment records with dates, response assessment | | OR: medical exception (contraindication/inappropriate) | Prescriber letter with clinical rationale | | Checkpoint inhibitor is guideline-supported for this indication | NCCN citation in prescriber letter; biomarker results | | Diagnosis and staging confirmed | Pathology report, imaging, staging workup |
A strong appeal letter leads with the guideline support for first-line use, then systematically addresses each step requirement, and closes with the impact of delay on disease progression.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →